Proteome Sciences PLC (GB:PRM)
LSE:PRM
Top Page
Proteome Sciences
(LSE:PRM)
Select Model
Select Model
Rating:42Neutral
Price Target:
2.00 p
▼(-29.82% Downside)
Action:DowngradedDate:01/27/26
The score is held down primarily by very weak financial performance (declining revenue, ongoing losses, negative cash flow, and negative equity). Technicals are also bearish with the stock below key moving averages, though oversold signals modestly offset the downside. Valuation is unfavorable due to a negative P/E and no dividend support.
Positive Factors
Specialized Proteomics Expertise
Proteome Sciences' core capability in mass spectrometry and biomarker discovery is a durable technical moat. High scientific complexity and specialized instrumentation create barriers to entry, supporting long-term client relationships with pharma/biotech and enabling premium, hard-to-replicate service offerings.
Negative Factors
Negative Equity / Solvency Risk
Negative stockholders' equity is a material solvency concern that limits financial flexibility. It raises the likelihood of higher funding costs or equity dilution, constrains investment in R&D and capacity expansion, and can impair long-term competitiveness if not remedied through sustained profitability or recapitalization.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized Proteomics Expertise
Proteome Sciences' core capability in mass spectrometry and biomarker discovery is a durable technical moat. High scientific complexity and specialized instrumentation create barriers to entry, supporting long-term client relationships with pharma/biotech and enabling premium, hard-to-replicate service offerings.
Read all positive factors
Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.54M
Dividend YieldN/A
Average Volume (3M)476.64K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth12.19%
EPS Growth18.12%
CountryUK
Employees36
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-1.54
Price to Sales (P/S)2.05
P/FCF Ratio-9.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Proteome Sciences Business Overview & Revenue Model
Company Description
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive an...
How the Company Makes Money
Proteome Sciences generates revenue primarily through its contract research services, which involve offering proteomics analysis and biomarker discovery to pharmaceutical and biotechnology companies. These services are often provided on a fee-for-...
Proteome Sciences Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.53M | 4.89M | 5.03M | 7.78M | 5.12M | 4.71M |
| Gross Profit | -32.00K | -167.00K | 1.16M | 4.77M | 2.96M | 2.54M |
| EBITDA | -1.45M | -1.44M | -986.00K | 1.89M | 725.00K | 691.00K |
| Net Income | -3.33M | -3.41M | -2.44M | 1.32M | 72.00K | 295.00K |
Balance Sheet | ||||||
| Total Assets | 8.35M | 9.21M | 11.46M | 12.43M | 10.04M | 9.09M |
| Cash, Cash Equivalents and Short-Term Investments | 263.00K | 1.13M | 2.03M | 3.99M | 2.39M | 2.21M |
| Total Debt | 15.39M | 14.52M | 13.47M | 11.91M | 11.69M | 11.04M |
| Total Liabilities | 16.93M | 15.72M | 14.52M | 13.28M | 12.82M | 12.45M |
| Stockholders Equity | -8.58M | -6.52M | -3.07M | -843.00K | -2.77M | -3.36M |
Cash Flow | ||||||
| Free Cash Flow | -1.48M | -1.05M | -718.00K | 2.14B | 8.80B | -9.07B |
| Operating Cash Flow | -1.21M | -826.00K | -481.00K | 3.88B | 10.52B | -7.74B |
| Investing Cash Flow | -273.00K | -224.00K | -424.00K | -21.67B | 4.27B | -18.38B |
| Financing Cash Flow | 368.00K | 151.00K | -1.06M | -209.00K | -400.00K | -146.00K |
Proteome Sciences Technical Analysis
Negative
2.85
Price Trends
1.75
Negative
2.10
Negative
2.38
Negative
Market Momentum
-0.07
Negative
33.91
Neutral
20.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 2.85 is above the 20-day moving average (MA) of 1.63, above the 50-day MA of 1.75, and above the 200-day MA of 2.38, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 33.91 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.
Proteome Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £7.19M | -0.39 | -122.54% | ― | -57.03% | -15.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £10.23M | -1.31 | -104.73% | ― | 29.64% | 28.51% | |
47 Neutral | £15.25M | -0.76 | -153.92% | ― | 90.42% | 79.21% | |
43 Neutral | £5.63M | -2.61 | -2.42% | ― | ― | ― | |
42 Neutral | £5.54M | -1.05 | 44.15% | ― | 12.19% | 18.12% | |
40 Underperform | £8.47M | -0.47 | -181.41% | ― | 12.12% | 54.24% |
* Healthcare Sector Average
GB:PRM
Proteome Sciences
1.58
-1.63
-50.78%
GB:CLBX
ANGLE plc
0.90
-6.85
-88.39%
GB:GDR
Genedrive
0.95
-0.57
-37.58%
GB:OPTI
OptiBiotix Health
5.45
-10.55
-65.94%
GB:VRCI
Verici Dx Plc
0.48
-1.57
-76.72%
GB:GENI
GENinCode UK Ltd.
1.13
-1.38
-55.00%
Proteome Sciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Proteome Sciences Launches £60,000 UK Retail Offer to Fund Proteomics Expansion
Positive
Jan 26, 2026
Proteome Sciences has launched a UK-only retail share offer of up to 3,428,571 new ordinary shares at 1.75 pence per share, aiming to raise up to £60,000 from existing retail shareholders via the BookBuild platform, in parallel with a separat...
Business Operations and StrategyPrivate Placements and Financing
Proteome Sciences Raises £840,000 to Accelerate Proteomics Expansion and Tightens Loan Conversion Terms
Positive
Jan 26, 2026
Proteome Sciences has raised £840,000 through a placing and subscription of 48 million new shares at 1.75p, representing about 14% of its enlarged share capital, and plans an additional retail offer of up to £60,000 at the same price via...
Business Operations and StrategyFinancial Disclosures
Proteome Sciences Wins Two More Major GCLP Contracts Worth Over $1.5m
Positive
Jan 6, 2026
Proteome Sciences has secured two additional substantial GCLP contracts worth over $1.5 million, following an earlier announcement in December 2025, with trial samples scheduled to be shipped in late Q1 and most of the work to be completed during ...
Business Operations and Strategy
Proteome Sciences Secures Major Biopharma Contract
Positive
Dec 8, 2025
Proteome Sciences has secured a significant contract with a US biopharmaceutical company to develop a new assay using its mass spectrometry services in Frankfurt, Germany. This contract, which adheres to Good Clinical Laboratory Practice standards...
Business Operations and StrategyExecutive/Board Changes
Proteome Sciences Appoints New Nominated Adviser and Broker
Positive
Nov 25, 2025
Proteome Sciences has announced the appointment of SP Angel Corporate Finance LLP as its new Nominated Adviser and sole Broker, effective immediately. This strategic move is expected to enhance the company’s development efforts and strengthe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.